Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia
Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Jean‐Pierre J. Issa(Coriell Institute For Medical Research), Gary L. Rosner(Johns Hopkins University), Jörge E. Cortes(Augusta University Health), Hui Yang(Hebei Medical University), Stefan Faderl(Jazz Pharmaceuticals (United States)), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Elihu H. Estey(University of Washington), Lianchun Xiao(The University of Texas MD Anderson Cancer Center), Blanca Sánchez‐González(The University of Texas MD Anderson Cancer Center), Carlos Bueso-Ramos(The University of Texas MD Anderson Cancer Center), Zeev Estrov(The University of Texas MD Anderson Cancer Center), Srđan Verstovšek(Unknown), William G. Wierda(University of Maryland, Baltimore), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Susan O’Brien(The University of Texas MD Anderson Cancer Center), Charles Koller(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Michael Rytting(The University of Texas MD Anderson Cancer Center), Jackie Fiorentino(The University of Texas MD Anderson Cancer Center)
Cited by 468
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k